Structural analysis

A platform to discuss high-level topics with the pharmaceutical industry

Novartis (Switzerland) and Alphora (Canada) joined the case study program conducted as part of the Second Annual Spring Pharmaceutical Synchrotron X-Ray...

More details More details

PARK INNOVAARE welcomes Excelsus Structural Solutions

Excelsus Structural Solutions (Swiss) AG, Villigen, a spin-off company of the Paul Scherrer Institute (PSI), has moved to PARK INNOVAARE’s deliveryLAB....

More details

Pharmaceutical formulations: Excelsus quantifies amorphous drug forms

Using state-of-the-art synchrotron X-ray powder diffraction at the Paul Scherrer Institute (PSI) and the pair distribution function (PDF) technique, Excelsus...

More details

Electron diffraction opens new possibilities for structure-based drug discovery

Modern pharmaceutical development is tailored to the chemical and physical characteristics of active organic compounds. The reason why the atomic structure...

More details

Pharmaceutical mixtures: Excelsus achieves an unprecedented level of detection

X-Ray Powder Diffraction (XRPD) is a powerful technique that exploits the interaction between X-rays and matter to study the structural and microstructural...

More details

Dr. Fabia Gozzo: "Our customers come from all over the world."

Interview with Dr. Fabia Gozzo, Founder and CEO of Excelsus Structural Solutions (Swiss) AG Excelsus Structural Solutions (Swiss) AG, Villigen, a spin-off...

More details
Subscribe to Structural analysis